Viyash Scientific’s Q3 EBITDA was up 64% to ₹185 crore.
Viyash Scientific (previously SeQuent Scientific), which has companies pursuits throughout Formulations, APIs and CDMO Companies, has reported that its December quarter web profit was up 15 per cent at ₹48 crore in opposition to ₹42 crore logged in the identical quarter final 12 months on the again of new product launches and value financial savings.
Income elevated 11 per cent to ₹858 crore (₹774 crore) whereas EBITDA was up 64 per cent to ₹185 crore (₹113 crore).
Viyash Lifesciences merged with SeQuent Scientific, creating India’s largest animal well being firm. The merger, valued at about ₹8,000 crore, combines SeQuent’s animal well being portfolio with Viyash’s human well being APIs and formulations. That is the primary time the corporate is saying the outcomes of the merged entity.
Dr Hari Babu Bodepudi, Managing Director and Group CEO, stated the monetary efficiency is a sign of the actions taken and the momentum the corporate has constructed throughout the previous couple of quarters, working as one crew.
Income, margins, profitability all have continued to indicate robust development on the again of new product introductions, value enchancment and synergies throughout enterprise items, he stated.
“We’ve a robust steadiness sheet and market place and are equipped for capturing the market alternative within the subsequent 3-5 years. The merger is beginning to generate advantages throughout R&D, manufacturing and front-end, all of which make us very excited for the journey forward,” he added.
Extra Like This
Revealed on February 7, 2026
Source link
#Viyash #Scientific #profit #rises #product #launches
